ERK inhibitor and use thereof

US11466013B2 · kind B2 · utility

Assignee

• Betta Pharmaceuticals Co., Ltd · CN

Inventors

• Hao Wu · Shanghai, CN
• Wei Gu · Zhejiang, CN
• Xiaojing Tang · Zhejiang, CN
• Wei Wang · Westborough, US
• Bo ZHAN · Zhejiang, CN
• Dongjie Feng · Zhejiang, CN
• Yongxin Ke · Zhejiang, CN
• Zhongyan Chen · Zhejiang, CN
• Yifei Shen · Zhejiang, CN
• Wenmao WU · Zhejiang, CN
• Xintao ZHAO · Zhejiang, CN
• Hong Lan · Beijing, CN
• Jiabing Wang · Lansdale, US
• Lieming DING · Zhejiang, CN

Key dates

• Filing date: Jun 6, 2019
• Grant date: Oct 11, 2022
• Expiry date: Jun 6, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.